This trial was for 76 weeks. There were actually three different phase 3 trials with over 2,000 patient volunteers. It was a huge study and Lily was very hopeful for success. The stock was hit hard on this news. The hope is that the failure was due to attacking the wrong protein, which is very likely as there has been a big change in AZ research since 2010, when this all got started. Today, the focus is much more on Tau rather than amyloid. There are also people who think that the drug would only work if it is started very early in the course of the disease. There was improvement for people who took the drug, but it wasn't statistically significant, or practically relevant. Data mining deeper may show that it works for some groups, particularly younger, newly DXed.

I'm in no way trying to put a damper on this type of research. I still believe that currently, it's our best hope (even more than Nilotinib). I just wanted to remind everyone that lowering a-syn levels, as it appears the three companies we are following can do, does not mean they will slow or stop PD progression. That still needs to be proven.